EQUITY of EVIL was designed to tell a story of suspense, to enlighten the reader, and to pursuade people to start thinking about the reality of our brave new world. The story holds no answers or suggests any resolution, but it reveals how business, greed, and the deceit of man can play a role in the exploitation of human life.
Entrepreneur, Rudy Mazzocchi has been in the trenches of starting over a dozen medical device and biotechnology companies since entering the field in the late 1980’s. His formula is quite simple: listen to what the key opinion leaders are identifying as the ‘unmet clinical needs’ in the industry and provide them with the best possible solution. In order to do so, Mazzocchi is not shy about asking questions such as “why not?” and “what if?” With potential solutions in hand, he then crafts his story for investors and recruits the best management and engineering teams possible to move the new venture forward.
Mazzocchi has been granted access to elite research institutions and universities throughout the world, providing him a first peek at medical innovations that are sometimes a decade away from being commercialized. His successful efforts provided him with a reputation of being one of the go-to businessmen in the medical industry, and is now building brand recognition as an international award-winning novelist.
Over the past two decades he has collected his share of notable industry awards, including the Ernst & Young Entrepreneur of the Year Award, Businessman of the Year Award – presented by the National Congressional Committee, and National Technology Leadership Award. Since the release of his debut novel, EQUITY of EVIL, in March of 2012, he has already picked up the 2012 Global eBook Award for Best Suspense Novel and the eLit Award for Best Suspense/Thriller Novel. His first book has also been nominated for the 2012 International Thriller Writer’s Award, 2012 ForeWord Book of the Year Award, 2013 Eric Hoffer Award, and 2013 Edgar’s Award for the Best First Novel.
When asked about his initial success, he indicates that his creative story-telling is a result of him continuing to ask those same questions; “why not?” and “what if?”. Mazzocchi’s next novel is the second in a series becoming known as The EQUITY Series; due for release near the first of the New Year. This unique series may potentially be the essence of a new genre that combines both business and medical science. To intensify the suspenseful elements of his stories, Mazzocchi makes it known that his novels are based on true events.